Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Receivables (2022 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Receivables for 4 consecutive years, with $19.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 49.85% year-over-year to $19.3 million, compared with a TTM value of $19.3 million through Sep 2025, up 49.85%, and an annual FY2024 reading of $12.9 million, up 46.18% over the prior year.
  • Receivables was $19.3 million for Q3 2025 at Fennec Pharmaceuticals, up from $17.5 million in the prior quarter.
  • Across five years, Receivables topped out at $19.3 million in Q3 2025 and bottomed at $1.5 million in Q4 2022.
  • Average Receivables over 4 years is $10.0 million, with a median of $11.3 million recorded in 2024.
  • The sharpest move saw Receivables skyrocketed 510.46% in 2024, then soared 42.15% in 2025.
  • Year by year, Receivables stood at $1.5 million in 2022, then skyrocketed by 470.49% to $8.8 million in 2023, then soared by 46.18% to $12.9 million in 2024, then soared by 50.13% to $19.3 million in 2025.
  • Business Quant data shows Receivables for FENC at $19.3 million in Q3 2025, $17.5 million in Q2 2025, and $15.4 million in Q1 2025.